Clinical Trials Logo

Recurrent Gliosarcoma clinical trials

View clinical trials related to Recurrent Gliosarcoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03360708 Not yet recruiting - Clinical trials for Recurrent Glioblastoma

Vaccine Therapy and Cytokine-Induced Killer Cells in Treating Patients With Recurrent Glioblastoma

Start date: December 29, 2017
Phase: Early Phase 1
Study type: Interventional

This pilot early phase I trial studies the side effects of vaccine therapy and cytokine-induced killer cells in treating patients with glioblastoma that has come back. Vaccines made from a person's white blood cells mixed with tumor proteins from another person's glioblastoma tumors may help the body build an effective immune response to kill tumor cells. Cytokine-induced killer cells are white blood cells with a powerful ability to kill tumor cells without any further modification. Giving vaccine therapy and cytokine-induced killer cells may work better in treating patients with glioblastoma.

NCT ID: NCT00883298 Completed - Clinical trials for Recurrent Glioblastoma Multiforme

Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme

Start date: April 2009
Phase: Phase 2
Study type: Interventional

Primary objective - to determine the 6-month progression free survival (PFS) of adult patients with recurrent glioblastoma multiforme/gliosarcoma treated with bi-weekly temozolomide plus (Avastin) bevacizumab. Secondary objectives - to determine radiographic response including specialized MRI sequences, safety and overall survival of adult patients with with recurrent glioblastoma multiforme/gliosarcoma treated with bi-weekly temozolomide plus bevacizumab (Avastin). Additionally, tumor DNA (MGMT) analysis as it relates to survival will be evaluated.